SOTROVIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Possibly Marketed Outside US

First approved in 2021

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 08:02:13 GMT 2025` Edited by `admin` on `Wed Apr 02 08:02:13 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	1MTK0BPN8V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SOTROVIMAB

Official Name

English

GSK-4182136

Preferred Name

English

sotrovimab [INN]

Common Name

English

VIR7831

Code

English

IMMUNOGLOBULIN G1 (438-LEUCINE,444-SERINE), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONAL VIR-7831 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIR-7831 .KAPPA.-CHAIN, DIMER

Common Name

English

Sotrovimab [WHO-DD]

Common Name

English

GSK4182136

Code

English

IMMUNOGLOBULIN G1-KAPPA, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (2019-NCOV) SPIKE GLYCOPROTEIN (PEPLOMER PROTEIN, E2)),HUMAN MONOCLONAL ANTIBODY; .GAMMA.1 HEAVY CHAIN (1-457) (HOMO SAPIENS VH (IGHV1-18*01 (93%) (IGHD)-IGHJ5*01 (93%)) (8.8.

Common Name

English

SOTROVIMAB [JAN]

Common Name

English

VIR-7831

Code

English

SOTROVIMAB [USAN]

Common Name

English

Code System Code Type Description

FDA UNII

1MTK0BPN8V

Created by admin on Wed Apr 02 08:02:13 GMT 2025 , Edited by admin on Wed Apr 02 08:02:13 GMT 2025

PRIMARY

INN

11766

Created by admin on Wed Apr 02 08:02:13 GMT 2025 , Edited by admin on Wed Apr 02 08:02:13 GMT 2025

PRIMARY

SMS_ID

300000022271

Created by admin on Wed Apr 02 08:02:13 GMT 2025 , Edited by admin on Wed Apr 02 08:02:13 GMT 2025

PRIMARY

WIKIPEDIA

Sotrovimab

Created by admin on Wed Apr 02 08:02:13 GMT 2025 , Edited by admin on Wed Apr 02 08:02:13 GMT 2025

PRIMARY

CAS

2423014-07-5

Created by admin on Wed Apr 02 08:02:13 GMT 2025 , Edited by admin on Wed Apr 02 08:02:13 GMT 2025

PRIMARY

DAILYMED

1MTK0BPN8V

Created by admin on Wed Apr 02 08:02:13 GMT 2025 , Edited by admin on Wed Apr 02 08:02:13 GMT 2025

PRIMARY

NCI_THESAURUS

C177059

Created by admin on Wed Apr 02 08:02:13 GMT 2025 , Edited by admin on Wed Apr 02 08:02:13 GMT 2025

PRIMARY

RXCUI

2550731

Created by admin on Wed Apr 02 08:02:13 GMT 2025 , Edited by admin on Wed Apr 02 08:02:13 GMT 2025

PRIMARY

USAN

JK-80

Created by admin on Wed Apr 02 08:02:13 GMT 2025 , Edited by admin on Wed Apr 02 08:02:13 GMT 2025

PRIMARY

From	To
1_22	1_96
2_22	2_96
2_154	2_210
2_230	4_214
2_271	2_331
1_154	1_210
2_377	2_435
3_23	3_89
3_134	3_194
4_23	4_89
4_134	4_194
1_230	3_214
1_236	2_236
1_239	2_239
1_271	1_331
1_377	1_435

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_307
N	2_307

Related Record Type Details


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->INHIBITOR

Amount:


					0EO1SV3LKY

SPIKE-1 PROTEIN SARS-COV-2

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					1MTK0BPN8V

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42
AMINO ACID REMOVAL	[1_457] [2_457]	C-TERMINUS			LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL